NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...

NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

On Monday, the European Commission approved GSK plc’s (NYSE:GSK) Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

UK's FTSE 100 firmed on Wednesday after two straight days of losses, buoyed by gains in shares of heavyweight GSK and gold ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore the potential of cancer prevention through vaccination.

Yet GSK is clearly healing from its multiple comorbidities — the worst of which was the (now largely resolved) legal overhang related to heartburn medicine Zantac. Chief executive Emma Walmsley also ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates ...

As we mentioned on Tuesday, the majority of companies on the S&P 500 that have reported earnings, have beaten estimates, and ...